SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Webull Corp. engages in the provision of financial services. It offers trading, wealth management product distribution, market data and information, user community, and investor education. The company was founded by An Quan Wang in 2016 and is headquartered in St. Petersburg, FL.

Webull Corp. - Ordinary Shares - Class A

Webull Corp

Webull ($BULL) is trending amid anticipation for its earnings report, with the community divided between those expecting a positive surprise and others bracing for a potential sell-off. Community discussion revolves around whether the stock can beat low expectations and overcome broader market concerns. Some traders are eyeing options activity and potential for a gamma squeeze following the report.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

The QQQ is experiencing significant volatility, driven by concerns around potential rate cuts and a possible overvaluation in the tech sector following earnings. Community sentiment is largely bearish, with many anticipating further declines and questioning the strength of the market. Traders are closely watching key support levels and the impact of broader market factors like cryptocurrency movements.

SSgA Active Trust - SPDR S&P 500 ETF Trust

The SPY is experiencing heavy volatility, triggering discussions around margin calls and potential bear market conditions. Community sentiment is mixed, with some anticipating a bounce while others brace for further declines, influenced by factors like crypto sell-offs and uncertainty surrounding Federal Reserve policy. Concerns about overvaluation and the impact of potential rate cuts are also driving market anxieties.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron is trending amid discussions about memory pricing and potential impacts from AI-driven demand, with some traders highlighting recent analyst upgrades while others are wary of a possible pullback after the stock's significant year-to-date gains. Community members are actively debating whether the stock is overbought and due for a correction, or if it still has room to run based on strong fundamentals and growing demand.

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is trending downwards, with the community expressing concerns over recent price drops and a lack of news regarding satellite launches. Investors are debating whether to buy the dip or cut losses, while also questioning the company's timeline for achieving revenue and profitability. Some speculate about market manipulation and broader economic factors affecting the stock's performance.

The Boeing Co. is an aerospace company, which engages in the manufacture of commercial jetliners and defense, space, and security systems. It operates through the following segments: Commercial Airplanes (BCA), Defense, Space and Security (BDS), Global Services (BGS), and Boeing Capital (BCC). The Commercial Airplanes segment includes the development, production, and market of commercial jet aircraft and provides fleet support services, principally to the commercial airline industry worldwide. The Defense, Space and Security segment refers to the research, development, production and modification of manned and unmanned military aircraft and weapons systems for global strike, including fighter and combat rotorcraft aircraft and missile systems, global mobility, including tanker, rotorcraft and tilt-rotor aircraft, and airborne surveillance and reconnaissance, including command and control, battle management and airborne anti-submarine aircraft. The Global Services segment provides services to commercial and defense customers. The Boeing Capital segment seeks to ensure that Boeing customers have the financing they need to buy and take delivery of their Boeing product and manages overall financing exposure. The company was founded by William Edward Boeing on July 15, 1916 and is headquartered in Arlington, VA.

Boeing Co.

Boeing Co

Boeing ($BA) is trending as the community discusses the stock's recent struggles despite positive developments like settling a strike and potential FAA approval for the 777X. Concerns persist around production stability, profitability, and the overall health of the company compared to its peers in the aerospace sector. Some traders speculate about share dilution and potential manipulation as driving forces behind the stock's downward trajectory.

Walmart, Inc. engages in the retail and wholesale business. The company offers an assortment of merchandise and services at everyday low prices. It operates through the following business segments: Walmart U.S., Walmart International, and Sam's Club. The Walmart U.S. segment operates as a mass merchandiser of consumer products, operating under the Walmart and Walmart Neighborhood Market brands, including walmart.com. The Walmart International segment includes operations of wholly-owned subsidiaries in Canada, Chile, China, and Africa, and majority-owned subsidiaries in India, as well as Mexico and Central America. The Sam's Club segment manages membership-only warehouse clubs and operates samsclub.com. The company was founded by Samuel Moore Walton and James Lawrence Walton on July 2, 1962 and is headquartered in Bentonville, AR.

Walmart Inc

Walmart is trending as investors digest recent earnings, a raised FY26 outlook, and the planned transfer of its stock listing to Nasdaq. Community members are discussing the stock's resilience amid a down market and speculating on potential price movements, as well as Walmart's increasing focus on technology and AI.

Applied Digital Corp. is a technology company, which engages in the provision of development and operation of data centers which provide computing power. It operates through the Data Center Hosting Business and HPC Hosting Business segments. The Data Center Hosting Business segment provides energized infrastructure services to crypto mining customers. The HPC Hosting Business segment focuses on the designing, constructing, and operating data centers tailored to support high power density applications like HPC and AI. The company was founded by Wesley Carl Cummins and Jason Zhang in May 2001 and is headquartered in Dallas, TX.

Applied Digital Corporation

APLD is trending due to anticipation surrounding NVDA's earnings report and its potential impact on the data center sector; the community is closely watching for any positive news that could trigger a rally. Recent price volatility and a high short interest have investors on edge, with many hoping for a significant short squeeze. Discussions also include upcoming announcements regarding senior note offerings and new hyperscaler partnerships.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X Shares

Direxion Daily Semiconductor Bull 3X Shares

SOXL is seeing volatile trading as investors debate the sustainability of the AI-driven semiconductor rally. Community members are closely watching for a potential market correction, with some anticipating a significant drop while others remain bullish on the sector's long-term prospects. NVIDIA's upcoming earnings and overall market sentiment are expected to be key drivers for SOXL's near-term performance.

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is experiencing volatility, sparking debates about potential double tops and the possibility of further declines, with some speculating about drops to significantly lower levels. Community sentiment is mixed, ranging from concern over losses to opportunistic buying strategies, while others reference past market cycles and potential future black swan events. Broader discussions include quantum computing threats, the influence of large holders, and the impact of macroeconomic factors.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Galmed Announces Meaningful Top Line Results from AM-001 Study of Aramchol Meglumine

Galmed Announces Meaningful Top Line Results from AM-001 Study of Aramchol Meglumine Galmed Announces Meaningful Top Line Results from AM-001 Study of Aramchol Meglumine PR Newswire RAMAT-GAN...

<ul class="summary-bullets"><li>Galmed reported new data showing that its Aramchol–Stivarga–Metformin combination improved tumor cell killing in GI cancer models.</li><li>The company plans to begin Phase 1b trials in early 2026 as key Stivarga patents near expiration.</li><li>Stocktwits users focused on possible dilution, SEC filings, and the timing of upcoming earnings.</li></ul>Galmed Pharmaceuticals shares&nbsp;rose on Monday, following four sessions of losses, after the company reported top-line results showing that a three-drug combination of Aramchol, Stivarga and Metformin significantly improved tumor-cell killing in gastrointestinal cancers.The stock closed up 1% at $1.05 before slipping 4.6% in after-hours trading.<h2 class="st-heading-2">Top-Line Results Highlight Triple-Drug Effect</h2>Galmed said the regimen of Aramchol, Stivarga and Metformin demonstrated a significant synergistic effect, improving tumor-cell killing both in vivo and in vitro. The company said the combination&nbsp;could be developed as a fixed-dose therapy that could strengthen the effect of Stivarga, Bayer’s top-selling cancer drug.According to the company, the combination may serve as a life-cycle IP strategy for Stivarga as key patents expire in Europe in August 2028 and in the U.S. in July 2032. Two new U.S. patent applications have been submitted.Galmed said the Aramchol-Stivarga combination is expected to enter Phase 1b clinical trials in early 2026 for metastatic colorectal cancer, hepatocellular carcinoma and cholangiocarcinoma, with a planned expansion cohort including Metformin.<h2 class="st-heading-2">Study Builds On Prior Findings</h2>An earlier May study reported that Aramchol enhanced the efficacy of regorafenib in gastrointestinal cancer models. In that study, Aramchol&nbsp;enhanced the breakdown of cellular material triggered by regorafenib and affected several cell-signaling pathways linked to tumor growth. The combination also reduced tumor growth in liver cancer models without harming normal tissue.The newly announced results include additional data on&nbsp;the use of Aramchol in combination with regorafenib and Metformin. The study reported that Aramchol showed anti-tumor activity on its own and when&nbsp;combined with the other two drugs, and that the three-drug combination produced a reinforcing effect, supporting further development as a combined treatment.<h2 class="st-heading-2">Clinical Path Ahead</h2>Allen Baharaff said a fixed-dose combination with Aramchol “could potentially become a life-cycle IP strategy for regorafenib to help delay the generic competition.”Baharaff said the company is preparing to initiate its Phase 1b study at VCU Massey Comprehensive Cancer Center in early 2026. He added that positive findings could support accelerated development of Aramchol across three gastrointestinal cancer indications and expand the company’s pipeline.<h2 class="st-heading-2">Stocktwits Users Flag Possible Dilution</h2>On Stocktwits, retail sentiment for Galmed was ‘extremely bullish’ amid a 12,950% surge in 24-hour message volume.<figure class="image"><img style="aspect-ratio:968/143;" src="https://news.stocktwits-cdn.com/glmd_ss_jpg_a183d03fe6.webp" alt="glmd ss.jpg" width="968" height="143"><figcaption>GLMD sentiment and message volume as of November 17 | Source: Stocktwits</figcaption></figure>One user said, “Now let's wait for SEC filing. Crossed my fingers. I will tell you, if no dilution SEC is filed today after market close or before market opens, then get ready for another run and this would be epic run”<stembedurl>https://stocktwits.com/madan_shatri/message/636516948</stembedurl>Another user commented that they anticipated earnings “any day” and suggested the stock might attempt “a runup” before a potential offering.<stembedurl>https://stocktwits.com/Jonsie/message/636511939</stembedurl>Galmed’s stock has declined 67% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

 In this photo illustration, the Galmed Pharmaceuticals logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Galmed Pharmaceuticals Stock Snaps 4-Day Losing Streak On Triple-Drug Cancer Breakthrough — Retail Sees Dilution Risks

Galmed reported new data showing that its Aramchol–Stivarga–Metformin combination improved tumor cell killing in GI cancer models.

Equity

Galmed Announces Top-line Results in Oncology MoA Studies: A 3-drug combination of Aramchol, Stivarga and Metformin Significantly Enhanced GI Tumor Cells, Killing In-vivo and In-vitro

Galmed Announces Top-line Results in Oncology MoA Studies: A 3-drug combination of Aramchol, Stivarga and Metformin Significantly Enhanced GI Tumor Cells, Killing In-vivo and In-vitro Galmed...

Galmed Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update

Galmed Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update Galmed Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update PR...

Galmed Pharmaceuticals (GLMD) shares rose sharply on Tuesday after the company reported positive preclinical data showing that its experimental drug Aramchol enhances the effectiveness of Regorafenib in liver and colon cancer models.Following the announcement, Galmed's stock rose by 10.6%, closing at $1.46 per share.&nbsp;According to the company, Aramchol improved the anti-tumor activity of Regorafenib — a multi-kinase inhibitor approved for liver and colorectal cancers — in both in-vitro and in-vivo settings.&nbsp;The combination also activated ATM and AMPK pathways while inhibiting mTORC1 and mTORC2, mechanisms known to play roles in cancer cell survival.Aramchol was also shown to work in combination with other kinase inhibitors like Sorafenib and Lenvatinib, though Regorafenib exhibited the strongest synergistic effects.&nbsp;The dual treatment suppressed tumor growth in hepatoma models without causing toxicity to normal tissues, the company said.Retail sentiment spiked following the update.&nbsp;On Stocktwits, message volume surged 4,480% over 24 hours, with sentiment marked as ‘extremely bullish.’Some retail investors suggested the stock could double from a previous $1.31 entry level.&nbsp;<stembedurl>https://stocktwits.com/debbiekatz/message/613719065</stembedurl>Others speculated the price could climb to the $2.50–$3.00 range, reflecting confidence ahead of the next trading session.<stembedurl>https://stocktwits.com/ZCOCSTOCK/message/613738896</stembedurl>Galmed said it expects to initiate a Phase 1b trial of Aramchol in combination with Regorafenib by the fourth quarter of 2025.The oncology update comes on the heels of another strategic development.&nbsp;Last week, Galmed signed a binding term sheet with Entomus s.r.o. for the licensing of a proprietary Self-Emulsifying Drug Delivery System (SEDDS) formulation.&nbsp;The technology enables sublingual absorption of peptides such as GLP-1, a key target in metabolic disorders.&nbsp;A definitive agreement outlining milestones and royalty terms is expected within 90 days.Shares of Galmed have fallen 56% so far this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

RBC said Medicaid spending was politically harder to unwind than the Journal suggested, adding that many small and rural hospitals depend on these payments to stay afloat. | Image source: Getty Images

Galmed Pharma Shares Jump 10% On Cancer Drug Data: Retail Traders Turn ‘Extremely Bullish’

The company reported that Aramchol, its experimental liver drug, enhanced Regorafenib’s anti-tumor effects without causing toxicity in preclinical models.

Galmed publishes Results from Aramchol Phase 3 Open Label part in Hepatology

Galmed publishes Results from Aramchol Phase 3 Open Label part in Hepatology Galmed publishes Results from Aramchol Phase 3 Open Label part in Hepatology PR Newswire TEL AVIV, Israel, Sept. 25, 2024...

Galmed Announces an Expansion of its Activities to Cancer and major Cardiometabolic Diseases

Galmed Announces an Expansion of its Activities to Cancer and major Cardiometabolic Diseases Galmed Announces an Expansion of its Activities to Cancer and major Cardiometabolic Diseases PR Newswire...

Galmed Pharmaceuticals Reports Mid-Year Loss

Galmed Pharmaceuticals (GLMD) has released an update. Galmed Pharmaceuticals Ltd. reports a net loss of $2.394 million for the first half of 2024...

Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2023

Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2023 Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended...

StockNews.com Begins Coverage on Galmed Pharmaceuticals (NASDAQ:GLMD)

StockNews.com initiated coverage on shares of Galmed Pharmaceuticals (NASDAQ:GLMD - Free Report) in a research report sent to investors on Sunday morning. The brokerage issued a sell rating on the...

Galmed Pharmaceuticals Ltd. is a clinical-stage drug development biopharmaceutical company, which engages in the development of oral therapy for the treatment of non-alcoholic steato-hepatitis (NASH). Its product candidate, Aramchol, is a synthetic fatty acid-bile acid conjugate molecule for the oral treatment of NASH in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company was founded by Allen Baharaff and Tuvia Gilat in 2000 and is headquartered in Tel Aviv, Israel.

Current Price	$0.8149
Prev Close	$0.9422
Open	$0.901
Dividend Yield	0.00%
50-Day Moving Average	$1.37
Beta	1.21
Avg. Volume	78,060.57
PE Ratio	-0.17

52-Week High	$3.61
52-Week Low	$0.94
Market Capitalization	$5.16M
EPS (Annual)	-$8.08
Price to Book	0.24
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

GLMD
Galmed Pharmaceuticals Ltd

Feed

News

Sentiment

Fundamentals

Info

Latest GLMD News

GLMDGalmed Pharmaceuticals Ltd